Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
crenolanib (ARO-002)
i
Other names:
ARO-002, CP-868,596, CP-868-596, CP-868,596-26, IND 112201
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(25)
News
Trials
Company:
AROG
Drug class:
FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor
Related drugs:
‹
quizartinib (40)
PHI-101 (12)
ripretinib (11)
MLN518 (8)
SU5614 (6)
pexidartinib (6)
CA-4948 (6)
CG-806 (6)
AST-487 (5)
CB-659 (4)
FF-10101 (3)
pacritinib (3)
CEP-701 (3)
BGS-2456 (2)
HPB-092 (2)
fedratinib (2)
JRF104 (2)
MEN1703 (2)
Max-40279 (2)
UNC2025 (2)
HEC73543 (2)
ABT-869 (2)
HM43239 (2)
TG02 (2)
AG-1296 (1)
AIU2008 (1)
CDDD11-8 (1)
D-65476 (1)
E6201 (1)
EC-70124 (1)
KC1036 (1)
KF-1601 (1)
KRC-108 (1)
PLD-102 (1)
STI-8591 (1)
XY0206 (1)
AM-5992 (0)
BMF-500 (0)
CCT137690 (0)
CLN-049 (0)
CTS2016 (0)
D-64406 (0)
EP0042 (0)
FLX925 (0)
FN-1501 (0)
4G8-SDIEM (0)
HYML-122 (0)
KW-2449 (0)
LT-171-861 (0)
MG-D-1509 (0)
MRX2843 (0)
NMS-088 (0)
R1530 (0)
RF-1302 (0)
SU 14813 (0)
SKI-G-801 (0)
flonoltinib (0)
SKLB-1028 (0)
NB003 (0)
MEDI-575 (0)
PTK787 (0)
quizartinib (40)
PHI-101 (12)
ripretinib (11)
MLN518 (8)
SU5614 (6)
pexidartinib (6)
CA-4948 (6)
CG-806 (6)
AST-487 (5)
CB-659 (4)
FF-10101 (3)
pacritinib (3)
CEP-701 (3)
BGS-2456 (2)
HPB-092 (2)
fedratinib (2)
JRF104 (2)
MEN1703 (2)
Max-40279 (2)
UNC2025 (2)
HEC73543 (2)
ABT-869 (2)
HM43239 (2)
TG02 (2)
AG-1296 (1)
AIU2008 (1)
CDDD11-8 (1)
D-65476 (1)
E6201 (1)
EC-70124 (1)
KC1036 (1)
KF-1601 (1)
KRC-108 (1)
PLD-102 (1)
STI-8591 (1)
XY0206 (1)
AM-5992 (0)
BMF-500 (0)
CCT137690 (0)
CLN-049 (0)
CTS2016 (0)
D-64406 (0)
EP0042 (0)
FLX925 (0)
FN-1501 (0)
4G8-SDIEM (0)
HYML-122 (0)
KW-2449 (0)
LT-171-861 (0)
MG-D-1509 (0)
MRX2843 (0)
NMS-088 (0)
R1530 (0)
RF-1302 (0)
SU 14813 (0)
SKI-G-801 (0)
flonoltinib (0)
SKLB-1028 (0)
NB003 (0)
MEDI-575 (0)
PTK787 (0)
›
Associations
(25)
News
Trials
VERI cancer hierarchy
Reset Filters
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3 mutation
Myelodysplastic Syndrome
FLT3 mutation
Myelodysplastic Syndrome
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3 D835
Acute Myelogenous Leukemia
FLT3 D835
Acute Myelogenous Leukemia
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
ARO-002
Sensitive: C2 – Inclusion Criteria
ARO-002
Sensitive
:
C2
FLT3 A848P + MLL-MLLT3 fusion
Acute Myelogenous Leukemia
FLT3 A848P + MLL-MLLT3 fusion
Acute Myelogenous Leukemia
ARO-002 + cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
ARO-002 + cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
ARO-002 + cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
ARO-002 + cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
FLT3-ITD mutation + MLL fusion + TP53 mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation + MLL fusion + TP53 mutation
Acute Myelogenous Leukemia
sorafenib + ARO-002
Sensitive: C3 – Early Trials
sorafenib + ARO-002
Sensitive
:
C3
sorafenib + ARO-002
Sensitive: C3 – Early Trials
sorafenib + ARO-002
Sensitive
:
C3
PDGFRB overexpression
Colorectal Cancer
PDGFRB overexpression
Colorectal Cancer
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
PDGFRA R841K
Melanoma
PDGFRA R841K
Melanoma
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
PDGFRA V658A
Melanoma
PDGFRA V658A
Melanoma
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
PDGFRA P577S
Melanoma
PDGFRA P577S
Melanoma
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
PDGFRA H845Y
Melanoma
PDGFRA H845Y
Melanoma
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
PDGFRA G853D
Melanoma
PDGFRA G853D
Melanoma
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
DNMT3A mutation
Acute Myelogenous Leukemia
DNMT3A mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
FLT3-ITD mutation + FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation + FLT3-TKD mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
ARO-002
Sensitive: C3 – Early Trials
ARO-002
Sensitive
:
C3
FLT3 F691L
Acute Myelogenous Leukemia
FLT3 F691L
Acute Myelogenous Leukemia
ARO-002
Sensitive: D – Preclinical
ARO-002
Sensitive
:
D
ARO-002
Sensitive: D – Preclinical
ARO-002
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
ARO-002 + Wu-5
Sensitive: D – Preclinical
ARO-002 + Wu-5
Sensitive
:
D
ARO-002 + Wu-5
Sensitive: D – Preclinical
ARO-002 + Wu-5
Sensitive
:
D
FLT3-ITD mutation + MLL rearrangement
Acute Myelogenous Leukemia
FLT3-ITD mutation + MLL rearrangement
Acute Myelogenous Leukemia
ARO-002 + MI-503
Sensitive: D – Preclinical
ARO-002 + MI-503
Sensitive
:
D
ARO-002 + MI-503
Sensitive: D – Preclinical
ARO-002 + MI-503
Sensitive
:
D
FLT3 Y842C
Acute Myelogenous Leukemia
FLT3 Y842C
Acute Myelogenous Leukemia
sorafenib + ARO-002
Sensitive: D – Preclinical
sorafenib + ARO-002
Sensitive
:
D
sorafenib + ARO-002
Sensitive: D – Preclinical
sorafenib + ARO-002
Sensitive
:
D
FLT3 N676D
Acute Myelogenous Leukemia
FLT3 N676D
Acute Myelogenous Leukemia
sorafenib + ARO-002
Sensitive: D – Preclinical
sorafenib + ARO-002
Sensitive
:
D
sorafenib + ARO-002
Sensitive: D – Preclinical
sorafenib + ARO-002
Sensitive
:
D
FLT3 N676D + FLT3 Y842C
Acute Myelogenous Leukemia
FLT3 N676D + FLT3 Y842C
Acute Myelogenous Leukemia
sorafenib + ARO-002
Sensitive: D – Preclinical
sorafenib + ARO-002
Sensitive
:
D
sorafenib + ARO-002
Sensitive: D – Preclinical
sorafenib + ARO-002
Sensitive
:
D
FLT3 N676T
Acute Myelogenous Leukemia
FLT3 N676T
Acute Myelogenous Leukemia
ARO-002
Sensitive: D – Preclinical
ARO-002
Sensitive
:
D
ARO-002
Sensitive: D – Preclinical
ARO-002
Sensitive
:
D
FLT3 D698N
Acute Myelogenous Leukemia
FLT3 D698N
Acute Myelogenous Leukemia
ARO-002
Sensitive: D – Preclinical
ARO-002
Sensitive
:
D
ARO-002
Sensitive: D – Preclinical
ARO-002
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login